PMID- 29121732
OWN - NLM
STAT- MEDLINE
DCOM- 20180627
LR  - 20220409
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 249
DP  - 2017 Dec 15
TI  - Quality of life improvement in older patients with heart failure initiated on 
      ivabradine: Results from the UK multi-centre LIVE:LIFE prospective cohort study.
PG  - 313-318
LID - S0167-5273(17)34166-9 [pii]
LID - 10.1016/j.ijcard.2017.08.001 [doi]
AB  - AIMS: LIVE:LIFE is a multi-centre, open-label, prospective observational cohort 
      study assessing health-related quality of life (HRQoL) in older patients with 
      chronic heart failure (CHF) following initiation of ivabradine. The primary 
      endpoint is change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) 
      total score after 6months. METHODS AND RESULTS: Consenting patients aged >/=70years 
      with CHF, in whom ivabradine was initiated within its licensed indication, were 
      enrolled. Demographic, clinical and HRQoL (MLWHFQ, SF-12) data were collected at 
      baseline (V1), 2 (V2) and 6months (V3). Over 14months, 240 patients were 
      recruited from 44 UK centres. Ninety-nine (41%) were female and 28% aged 
      >/=80years. Aetiology was ischaemic in 152 (63%) and 59% had been diagnosed with 
      CHF for </=2yrs. 52% of patients were New York Heart Association (NYHA) Class III 
      and 57% had left ventricular ejection fraction <35%. 57% received beta-blockers. 
      Patients had multiple comorbidities (144 (60%) hypertension, 105 (44%) 
      asthma/COPD, 80 (33%) diabetes) and were prescribed a mean of 9+/-3 daily 
      medications. Resting heart rate was 83bpm at baseline and fell 13bpm by V3. In 
      patients completing both visits (n=187), comparing V3 to baseline: MLWHFQ total 
      score improved by 9 points (p<0.0001, 95% CI: 7-12); 30% of patients improved >/=1 
      NYHA class and global assessment improved from patient (59%) and physician (60%) 
      perspectives. 88% of patients completing V3 were still taking ivabradine. 
      CONCLUSIONS: These contemporary prospective UK data demonstrate improvements in 
      HRQoL and functional status with ivabradine therapy in typical older CHF 
      patients. Despite comorbidities and polypharmacy, ivabradine was well tolerated.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Zachariah, D
AU  - Zachariah D
AD  - Portsmouth Hospitals NHS Trust, Portsmouth, UK. Electronic address: 
      donah.zachariah@nhs.net.
FAU - Stevens, D
AU  - Stevens D
AD  - Medical Affairs Department, Servier Laboratories, UK.
FAU - Sidorowicz, G
AU  - Sidorowicz G
AD  - Medical Affairs Department, Servier Laboratories, UK.
FAU - Spooner, C
AU  - Spooner C
AD  - Medical Affairs Department, Servier Laboratories, UK.
FAU - Rowell, N
AU  - Rowell N
AD  - South Tees Hospitals NHS Foundation Trust, UK.
FAU - Taylor, J
AU  - Taylor J
AD  - Glasgow Royal Infirmary, UK.
FAU - Kay, R
AU  - Kay R
AD  - School of Pharmacy and Pharmaceutical Sciences, Cardiff University, UK.
FAU - Salek, M S
AU  - Salek MS
AD  - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
FAU - Kalra, P R
AU  - Kalra PR
AD  - Portsmouth Hospitals NHS Trust, Portsmouth, UK.
CN  - LIVE:LIFE study investigators
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Benzazepines)
RN  - 0 (Cardiovascular Agents)
RN  - 3H48L0LPZQ (Ivabradine)
SB  - IM
CIN - Int J Cardiol. 2017 Dec 15;249:330-331. PMID: 29121737
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzazepines/*therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/*epidemiology/psychology
MH  - Humans
MH  - Ivabradine
MH  - Male
MH  - Prospective Studies
MH  - *Quality of Life/psychology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
OTO - NOTNLM
OT  - Elderly
OT  - HRQoL
OT  - Health-related quality of life
OT  - Heart failure
OT  - Ivabradine
OT  - MLWHFQ
EDAT- 2017/11/11 06:00
MHDA- 2018/06/28 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/07/09 00:00 [received]
PHST- 2017/08/01 00:00 [accepted]
PHST- 2017/11/11 06:00 [entrez]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2018/06/28 06:00 [medline]
AID - S0167-5273(17)34166-9 [pii]
AID - 10.1016/j.ijcard.2017.08.001 [doi]
PST - ppublish
SO  - Int J Cardiol. 2017 Dec 15;249:313-318. doi: 10.1016/j.ijcard.2017.08.001.